CervoMed Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
CervoMed Inc. (CRVO) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $4.49 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-07
- CervoMed Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $4.80, a 108.70% increase year-over-year.
- CervoMed Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.30, a 75.84% decline year-over-year.
- CervoMed Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $9.52.
- CervoMed Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.00.
- CervoMed Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $4.61, a 60.90% decline from fiscal 2024.
- CervoMed Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $11.79, a 98.15% increase from fiscal 2023.
- CervoMed Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $5.95, a 39.72% decline from fiscal 2022.
- CervoMed Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $9.87, a 77.90% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4.49 10-Q · filed 2026-08-07 | |||||
| 2026-03-31 | $4.80 10-Q · filed 2026-05-15 | |||||
| 2025-12-31 | $4.61 10-K · filed 2026-03-13 | |||||
| 2025-09-30 | $3.63 10-Q · filed 2025-11-07 | |||||
| 2025-06-30 | $3.63 10-Q · filed 2025-08-08 | |||||
| 2025-03-31 | $2.30 10-Q · filed 2025-05-12 | |||||
| 2024-12-31 | $11.79 10-K · filed 2025-03-17 | |||||
| 2024-09-30 | $11.23 10-Q · filed 2024-11-12 | |||||
| 2024-06-30 | $11.23 10-Q · filed 2024-08-09 | |||||
| 2024-03-31 | $9.52 10-Q · filed 2024-05-14 | |||||
| 2023-12-31 | $5.95 10-K · filed 2024-03-29 | |||||
| 2023-09-30 | $313.67 10-Q · filed 2023-11-13 | |||||
| 2023-06-30 | $0.00 10-Q · filed 2023-08-08 | |||||
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | |||||
| 2022-12-31 | $9.87 10-K · filed 2023-03-24 | |||||
| 2022-09-30 | $9.87 10-Q · filed 2022-11-14 | |||||
| 2022-06-30 | $11.40 10-Q · filed 2022-08-12 | |||||
| 2021-12-31 | $44.66 10-K · filed 2023-03-24 | $0.89 10-K · filed 2022-03-18 | ||||
| 2021-09-30 | $0.91 10-Q · filed 2021-11-10 | |||||
| 2021-06-30 | $1.10 10-Q · filed 2021-08-11 | |||||
| 2021-03-31 | $12.00 10-Q · filed 2022-05-12 | $1.11 10-Q · filed 2021-05-07 | ||||
| 2020-12-31 | $0.68 10-K · filed 2022-03-18 | |||||
| 2020-09-30 | $0.66 10-Q · filed 2020-11-12 | |||||
| 2020-06-30 | $0.58 10-Q · filed 2020-08-07 | |||||
| 2020-03-31 | $0.47 10-Q · filed 2020-05-11 | |||||
| 2019-12-31 | $2.62 10-K · filed 2021-03-17 | |||||
| 2019-09-30 | $2.62 10-Q · filed 2019-11-08 | |||||
| 2019-06-30 | $2.62 10-Q · filed 2019-08-08 | |||||
| 2019-03-31 | $2.10 10-Q · filed 2019-05-09 | |||||
| 2018-12-31 | $15.37 10-K · filed 2020-03-17 | |||||
| 2018-09-30 | $1.02 10-Q · filed 2018-11-13 | |||||
| 2018-06-30 | $1.02 10-Q · filed 2018-08-10 | |||||
| 2018-03-31 | $1.18 10-Q · filed 2018-05-10 | |||||
| 2017-12-31 | $36.92 10-K · filed 2019-03-19 | $2.46 10-K · filed 2018-04-02 | ||||
| 2017-09-30 | $2.49 10-Q · filed 2017-11-13 | |||||
| 2017-06-30 | $2.54 10-Q · filed 2017-08-14 | |||||
| 2017-03-31 | $2.33 10-Q · filed 2017-05-15 | |||||
| 2016-12-31 | $6.25 10-K · filed 2018-04-02 | |||||
| 2016-09-30 | $8.89 10-Q · filed 2016-11-14 | |||||
| 2016-06-30 | $0.96 10-Q · filed 2016-08-15 | |||||
| 2015-12-31 | $1.90 10-K · filed 2016-03-25 | |||||
| 2014-12-31 | $3.71 10-K · filed 2016-03-25 | |||||
| 2013-12-31 | $3.00 10-K · filed 2015-04-03 | |||||
| 2012-12-31 | $0.36 10-Q/A · filed 2013-05-20 | |||||
| 2012-09-30 | $0.36 10-Q · filed 2012-11-19 | |||||
| 2012-06-30 | $0.35 10-Q/A · filed 2012-09-07 | |||||
| 2011-12-31 | $0.54 10-K/A · filed 2013-04-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |